XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Jul. 09, 2019
Collaboration And Other Agreements [Line Items]              
Revenues   $ 18,253 $ 18,741 $ 52,192 $ 38,996    
Deferred revenue, current   9,259   9,259   $ 10,700  
Deferred revenue, net of current portion   5,778   5,778   9,153  
I-Mab | I-Mab Biopharma Collaboration and License Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment $ 15,000            
Potential development and regulatory milestone payments under agreement             $ 135,000
Estimated variable consideration $ 1,000            
Revenues   1,000 $ 600 3,500 $ 600    
Deferred revenue   10,000   10,000   13,500  
Deferred revenue, current   4,300   4,300   4,400  
Deferred revenue, net of current portion   $ 5,700   $ 5,700   $ 9,100  
I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum              
Collaboration And Other Agreements [Line Items]              
Potential proceeds from royalties (percent) 20.00%